Mainz Biomed BV (MYNZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has a cash flow conversion efficiency ratio of -6.957x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.46 Million) by net assets ($641.60K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Mainz Biomed BV for the company's overall valuation and market capitalisation.
Mainz Biomed BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mainz Biomed BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mainz Biomed BV ranked by their cash flow conversion efficiency. See how well can Mainz Biomed BV service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HiteJinro Co Ltd
KO:000087
|
0.090x |
|
Kore Mining Ltd
V:KORE
|
0.029x |
|
Af Legal Group Ltd
AU:AFL
|
-0.015x |
|
Greenland Mines Ltd
NASDAQ:GRML
|
-0.113x |
|
SWS Capital Bhd
KLSE:7186
|
0.005x |
|
Domino’s Pizza Group PLC
LSE:DOM
|
-0.629x |
|
AirIQ Inc
V:IQ
|
0.049x |
|
Nala Digital Commerce Ltd
TA:NALA
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Mainz Biomed BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mainz Biomed BV from 2019 to 2025. View Mainz Biomed BV stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $641.60K | $-10.98 Million | -17.113x | -505.46% |
| 2024-12-31 | $6.05 Million | $-17.09 Million | -2.826x | +58.14% |
| 2023-12-31 | $3.25 Million | $-21.94 Million | -6.752x | -544.41% |
| 2022-12-31 | $14.10 Million | $-14.77 Million | -1.048x | -106.97% |
| 2021-12-31 | $6.36 Million | $-3.22 Million | -0.506x | -396.10% |
| 2020-12-31 | $-2.74 Million | $-468.74K | 0.171x | -19.94% |
| 2019-12-31 | $-1.95 Million | $-416.50K | 0.214x | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more